Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

PTGXProtagonist Therapeutics, Inc

Nasdaq · CIK 0001377121
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts356

Identity from submissions API

NameProtagonist Therapeutics, Inc
CIK0001377121
TickersPTGX
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN980505495
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(510) 474-0170
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Protagonist Therapeutics Inc (2013-06-11T00:00:00.000Z → 2013-06-11T00:00:00.000Z)
  • Protagonist Inc (2006-09-28T00:00:00.000Z → 2006-09-28T00:00:00.000Z)
Business address
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
CA
Mailing address
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

710 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 4 OWNERSHIP DOCUMENT 0001104659-26-130668 5237
2026-11-17 144 xsl144X01/primary_doc.xml 0001104659-26-129246 001-37852 261567810 33 4554
2026-11-17 4 OWNERSHIP DOCUMENT 0001104659-26-129244 5165
2026-11-06 10-Q 10-Q 0001104659-26-123620 001-37852 261529563 34 6740428 1 1
2026-11-05 8-K FORM 8-K 2.02,9.01 0001104659-26-123351 001-37852 261527689 34 325108 1 1
2026-10-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003834 005-89601 261491686 34 11207
2026-10-02 4 OWNERSHIP DOCUMENT 0001104659-26-113279 22973
2026-09-30 144 xsl144X01/primary_doc.xml 0001950047-26-009883 001-37852 261427386 33 4913
2026-09-10 4 OWNERSHIP DOCUMENT 0001104659-26-106831 20743
2026-09-08 4 OWNERSHIP DOCUMENT 0001104659-26-105955 5236
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000908834-26-000405 005-89601 261274961 34 49483
2026-08-12 4 OWNERSHIP DOCUMENT 0001104659-26-095111 15187
2026-08-10 144 xsl144X01/primary_doc.xml 0001968582-26-000805 001-37852 261259216 33 5716
2026-08-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000527 005-89601 261252250 34 8278
2026-08-05 S-8 POS S-8 POS 0001104659-26-091259 333-293749 261244773 33 109280
2026-08-05 S-8 POS S-8 POS 0001104659-26-091257 333-285137 261244764 33 109280
2026-08-05 S-8 POS S-8 POS 0001104659-26-091254 333-277409 261244750 33 109280
2026-08-05 S-8 POS S-8 POS 0001104659-26-091249 333-270573 261244738 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091245 333-263097 261244720 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091242 333-254090 261244703 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091241 333-237066 261244691 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091239 333-230213 261244679 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091236 333-223500 261244668 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091235 333-216532 261244655 33 109271
2026-08-05 S-8 POS S-8 POS 0001104659-26-091233 333-213120 261244648 33 109271
2026-08-05 S-8 FORM S-8 0001104659-26-091226 333-298024 261244636 33 213341 1 1
2026-08-05 10-Q 10-Q 0001104659-26-091123 001-37852 261243821 34 6680490 1 1
2026-08-05 8-K FORM 8-K 2.02,7.01,9.01 0001104659-26-091099 001-37852 261243623 34 8452992 1 1
2026-06-25 4 OWNERSHIP DOCUMENT 0001104659-26-077761 9419
2026-06-23 144 xsl144X01/primary_doc.xml 0001950047-26-006422 001-37852 261111369 33 6437
2026-06-18 8-K FORM 8-K 5.02,5.07,9.01 0001104659-26-075777 001-37852 261103234 34 389823 1 1
2026-06-11 4 OWNERSHIP DOCUMENT 0001104659-26-073049 13059
2026-06-10 144 xsl144X01/primary_doc.xml 0001950047-26-005894 001-37852 261080072 33 5719
2026-06-01 4 OWNERSHIP DOCUMENT 0001104659-26-069047 8945
2026-05-29 144 xsl144X01/primary_doc.xml 0001950047-26-005290 001-37852 261044828 33 4988
2026-05-14 4/A OWNERSHIP DOCUMENT 0001104659-26-061476 9736
2026-05-12 4 OWNERSHIP DOCUMENT 0001104659-26-059591 9307
2026-05-12 144 xsl144X01/primary_doc.xml 0001968582-26-000430 001-37852 26970036 33 5712
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000283 005-89601 26966949 34 8374
2026-05-11 4 OWNERSHIP DOCUMENT 0001104659-26-058860 17758
2026-05-08 144 xsl144X01/primary_doc.xml 0001950047-26-004264 001-37852 26958734 33 6900
2026-05-07 144 xsl144X01/primary_doc.xml 0001950047-26-004220 001-37852 26954935 33 4841
2026-05-07 144 xsl144X01/primary_doc.xml 0001950047-26-004218 001-37852 26954485 33 5458
2026-05-05 10-Q 10-Q 0001104659-26-055661 001-37852 26943692 34 6058814 1 1
2026-05-05 8-K FORM 8-K 2.02,9.01 0001104659-26-055629 001-37852 26943101 34 275227 1 1
2026-04-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-000884 005-89601 26921820 34 7592
2026-04-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100121-26-000589 005-89601 26914287 34 7536
2026-04-28 ARS ARS 0001104659-26-050443 001-37852 26908879 34 2111795
2026-04-28 DEFA14A DEFA14A 0001104659-26-050440 001-37852 26908820 34 438551
2026-04-28 DEF 14A FORM- DEF 14A 0001104659-26-050429 001-37852 26908719 34 3904304 1 1
2026-04-24 4 OWNERSHIP DOCUMENT 0001104659-26-048572 5245
2026-04-21 4 OWNERSHIP DOCUMENT 0001104659-26-046110 5134
2026-04-21 144 xsl144X01/primary_doc.xml 0001104659-26-046107 001-37852 26880334 33 5749
2026-03-27 4 OWNERSHIP DOCUMENT 0001104659-26-036319 9421
2026-03-27 4 OWNERSHIP DOCUMENT 0001104659-26-036318 8688
2026-03-27 4 OWNERSHIP DOCUMENT 0001104659-26-036317 13454
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002110 005-89601 26803089 34 7357
2026-03-26 144 xsl144X01/primary_doc.xml 0001950047-26-003020 001-37852 26798083 33 4853
2026-03-26 144 xsl144X01/primary_doc.xml 0001950047-26-003018 001-37852 26798057 33 6229
2026-03-26 144 xsl144X01/primary_doc.xml 0001950047-26-003011 001-37852 26797982 33 7680
2026-03-25 4 OWNERSHIP DOCUMENT 0001104659-26-034736 15738
2026-03-24 144 xsl144X01/primary_doc.xml 0001968582-26-000318 001-37852 26787767 33 6463
2026-02-25 S-8 FORM S-8 0001104659-26-019736 333-293749 26679455 33 199205 1 1
2026-02-25 10-K 10-K 0001104659-26-019696 001-37852 26679116 34 12941373 1 1
2026-02-25 8-K FORM 8-K 2.02,9.01 0001104659-26-019658 001-37852 26678583 34 296698 1 1
2026-02-18 4 OWNERSHIP DOCUMENT 0001104659-26-017176 9041
2026-02-17 144 xsl144X01/primary_doc.xml 0001950047-26-001404 001-37852 26643747 33 4858
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493215-26-000042 005-89601 26636753 34 12813
2026-02-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-26-000033 005-89601 26614256 34 15393
2026-02-06 4 OWNERSHIP DOCUMENT 0001104659-26-011575 9068
2026-02-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000908834-26-000054 005-89601 26607705 34 64693
2026-02-06 144 xsl144X01/primary_doc.xml 0001950047-26-000988 001-37852 26607551 33 4908
2026-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000253 005-89601 26582584 34 7194
2026-01-27 4 OWNERSHIP DOCUMENT 0001104659-26-007129 27682
2026-01-27 4 OWNERSHIP DOCUMENT 0001104659-26-007128 15274
2026-01-27 4 OWNERSHIP DOCUMENT 0001104659-26-007127 16354
2026-01-27 144 xsl144X01/primary_doc.xml 0001950047-26-000710 001-37852 26567014 33 9052
2026-01-27 144 xsl144X01/primary_doc.xml 0001950047-26-000698 001-37852 26565338 33 7677
2026-01-26 144 xsl144X01/primary_doc.xml 0001950047-26-000681 001-37852 26560837 33 6969
2026-01-23 144 xsl144X01/primary_doc.xml 0001950047-26-000655 001-37852 26556938 33 8029
2026-01-23 144 xsl144X01/primary_doc.xml 0001968582-26-000059 001-37852 26556432 33 5065
2026-01-21 4 OWNERSHIP DOCUMENT 0001104659-26-005443 5025
2026-01-21 4 OWNERSHIP DOCUMENT 0001104659-26-005442 5110
2026-01-21 4 OWNERSHIP DOCUMENT 0001104659-26-005440 4995
2026-01-21 144 xsl144X01/primary_doc.xml 0001104659-26-005438 001-37852 26548836 33 5152
2026-01-21 144 xsl144X01/primary_doc.xml 0001104659-26-005437 001-37852 26548831 33 4613
2026-01-21 144 xsl144X01/primary_doc.xml 0001104659-26-005435 001-37852 26548811 33 4480
2026-01-13 4 OWNERSHIP DOCUMENT 0001104659-26-003386 7067
2026-01-12 8-K FORM 8-K 7.01,9.01 0001104659-26-002724 001-37852 26524735 34 13562274 1 1
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001479 7500
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001478 7549
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001477 8199
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001476 7520
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001475 7478
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001474 7670
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001472 7553
2026-01-06 4 OWNERSHIP DOCUMENT 0001104659-26-001471 7586
2025-11-24 4 OWNERSHIP DOCUMENT 0001104659-25-115399 5101
2025-11-19 4 OWNERSHIP DOCUMENT 0001104659-25-114082 5027
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-003110 005-89601 251486594 34 23542
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-004833 005-89601 251481421 34 11551
2025-11-06 10-Q 10-Q 0001104659-25-107816 001-37852 251459296 34 6826171 1 1
2025-11-06 8-K FORM 8-K 2.02,9.01 0001104659-25-107753 001-37852 251458611 34 302687 1 1
2025-10-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-002687 005-89601 251401884 34 11120
2025-10-14 4 OWNERSHIP DOCUMENT 0001104659-25-099252 10778
2025-10-10 144 xsl144X01/primary_doc.xml 0001950047-25-007903 001-37852 251388323 33 6434
2025-09-24 4 OWNERSHIP DOCUMENT 0001104659-25-093046 5066
2025-09-22 144 xsl144X01/primary_doc.xml 0001950047-25-007415 001-37852 251330424 33 5728
2025-09-18 4 OWNERSHIP DOCUMENT 0001104659-25-091352 5094
2025-08-29 4 OWNERSHIP DOCUMENT 0001104659-25-085795 5066
2025-08-27 144 xsl144X01/primary_doc.xml 0001950047-25-006453 001-37852 251265758 33 4997
2025-08-11 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-25-000483 005-89601 251200262 34 8324
2025-08-06 S-3ASR S-3ASR 0001104659-25-074748 333-289313 251190370 33 1250770 1 1
2025-08-06 10-Q 10-Q 0001558370-25-010534 001-37852 251189986 34 6752165 1 1
2025-08-06 8-K FORM 8-K 2.02,9.01 0001104659-25-074719 001-37852 251189718 34 304162 1 1
2025-07-28 4 OWNERSHIP DOCUMENT 0001104659-25-071262 5402
2025-07-23 4 OWNERSHIP DOCUMENT 0001104659-25-070104 10825
2025-07-22 144 xsl144X01/primary_doc.xml 0001968582-25-000616 001-37852 251140329 33 7197
2025-07-18 4 OWNERSHIP DOCUMENT 0001104659-25-069011 5403
2025-06-26 8-K FORM 8-K 5.07 0001104659-25-063038 001-37852 251080433 34 208244 1 1
2025-06-17 4 OWNERSHIP DOCUMENT 0001104659-25-060239 6617
2025-06-16 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-001771 005-89601 251051206 34 38535
2025-06-11 4 OWNERSHIP DOCUMENT 0001104659-25-058597 14884
2025-06-10 144 xsl144X01/primary_doc.xml 0001950047-25-004118 001-37852 251038289 33 6265
2025-06-09 144 xsl144X01/primary_doc.xml 0001950047-25-004047 001-37852 251034746 33 5556
2025-05-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-25-000309 005-89601 25938508 34 8226
2025-05-06 10-Q 10-Q 0001558370-25-006530 001-37852 25918192 34 5970175 1 1
2025-05-06 8-K FORM 8-K 2.02,9.01 0001104659-25-045073 001-37852 25917689 34 302399 1 1
2025-04-30 4 OWNERSHIP DOCUMENT 0001104659-25-042608 6951
2025-04-29 ARS ARS 0001104659-25-041224 001-37852 25887662 34 20242420
2025-04-29 DEFA14A DEFA14A 0001104659-25-041217 001-37852 25887441 34 1138156
2025-04-29 DEF 14A DEF 14A 0001104659-25-041206 001-37852 25887164 34 3516303 1 1
2025-04-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001890 005-89601 25886134 34 11286
2025-04-23 4 OWNERSHIP DOCUMENT 0001104659-25-038036 4996
2025-04-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-001475 005-89601 25828563 34 11400
2025-03-20 8-K FORM 8-K 8.01 0001104659-25-026135 001-37852 25756563 34 197751 1 1
2025-03-19 4 OWNERSHIP DOCUMENT 0001104659-25-025535 5072
2025-03-17 144 xsl144X01/primary_doc.xml 0001950047-25-001945 001-37852 25744977 33 5012
2025-03-14 4 OWNERSHIP DOCUMENT 0001104659-25-024063 13033
2025-03-14 4 OWNERSHIP DOCUMENT 0001104659-25-024062 13107
2025-03-13 144 xsl144X01/primary_doc.xml 0001972362-25-000299 001-37852 25736934 33 4995
2025-03-12 144 xsl144X01/primary_doc.xml 0001972362-25-000282 001-37852 25732967 33 4970
2025-03-11 8-K/A FORM 8-K/A 8.01,9.01 0001104659-25-022615 001-37852 25728759 34 342779 1 1
2025-03-10 8-K FORM 8-K 8.01,9.01 0001104659-25-021986 001-37852 25722244 34 341297 1 1
2025-03-05 4 OWNERSHIP DOCUMENT 0001104659-25-021045 7182
2025-03-03 8-K FORM 8-K 8.01,9.01 0001104659-25-019516 001-37852 25693870 34 2782598 1 1
2025-02-21 S-8 FORM S-8 0001104659-25-016166 333-285137 25652730 33 221315 1 1
2025-02-21 10-K 10-K 0001558370-25-001317 001-37852 25652528 34 13189815 1 1
2025-02-21 8-K FORM 8-K 2.02,9.01 0001104659-25-015897 001-37852 25648457 34 310310 1 1
2025-02-20 4 OWNERSHIP DOCUMENT 0001104659-25-015734 5116
2025-02-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000908834-25-000053 005-89601 25603869 34 58907
2025-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-001236 005-89601 25592239 34 12080
2025-01-17 4 OWNERSHIP DOCUMENT 0001104659-25-004571 6550
2025-01-17 4 OWNERSHIP DOCUMENT 0001104659-25-004570 5154
2025-01-17 4 OWNERSHIP DOCUMENT 0001104659-25-004569 6521
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001435 7563
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001434 7491
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001432 7572
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001430 7396
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001429 7684
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001428 8212
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001427 7596
2025-01-06 4 OWNERSHIP DOCUMENT 0001104659-25-001426 7566
2025-01-06 8-K FORM 8-K 5.02 0001104659-25-001304 001-37852 25511067 34 197096 1 1
2024-11-27 4 OWNERSHIP DOCUMENT 0001104659-24-123809 20446
2024-11-27 4 OWNERSHIP DOCUMENT 0001104659-24-123807 25910
2024-11-27 4 OWNERSHIP DOCUMENT 0001104659-24-123806 13052
2024-11-27 144 xsl144X01/primary_doc.xml 0001972362-24-001771 001-37852 241511834 33 6201
2024-11-26 144 xsl144X01/primary_doc.xml 0001972362-24-001760 001-37852 241505953 33 5030
2024-11-26 144 xsl144X01/primary_doc.xml 0001972362-24-001758 001-37852 241505949 33 4991
2024-11-25 144 xsl144X01/primary_doc.xml 0001972362-24-001735 001-37852 241497429 33 4380
2024-11-25 144 xsl144X01/primary_doc.xml 0001968582-24-001046 001-37852 241495984 33 4815
2024-11-21 4 OWNERSHIP DOCUMENT 0001104659-24-121501 5109
2024-11-19 4 OWNERSHIP DOCUMENT 0001104659-24-120670 5034
2024-11-18 8-K FORM 8-K 1.01,8.01,9.01 0001104659-24-120165 001-37852 241471986 34 241941 1 1
2024-11-14 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0000921895-24-002719 005-89601 241463005 34 280393
2024-11-12 SC 13G/A UnitedStates_13G__Protagonis.txt 0000932471-24-001157 005-89601 241449407 34 6765
2024-11-07 10-Q 10-Q 0001558370-24-014888 001-37852 241436563 34 7075393 1 1
2024-11-07 8-K FORM 8-K 2.02,9.01 0001104659-24-115303 001-37852 241435679 34 299512 1 1
2024-11-04 SC 13G/A UnitedStates_13G__Protagonis.txt 0000932471-24-000563 005-89601 241422117 34 5800
2024-10-16 SC 13G Protagonist_Thera_Inc.htm 0000093751-24-000765 005-89601 241374016 34 56187
2024-09-20 8-K FORM 8-K 5.02 0001104659-24-101688 001-37852 241313403 34 198493 1 1
2024-09-13 4 OWNERSHIP DOCUMENT 0001104659-24-099838 14546
2024-09-12 4 OWNERSHIP DOCUMENT 0001104659-24-099420 8793
2024-09-11 144 xsl144X01/primary_doc.xml 0001972362-24-001324 001-37852 241293490 33 4899
2024-09-10 144 xsl144X01/primary_doc.xml 0001950047-24-006924 001-37852 241290305 33 5721
2024-08-07 SC 13G/A us74366e1029_080724.txt 0001086364-24-008384 005-89601 241183775 34 14112
2024-08-06 10-Q 10-Q 0001558370-24-011095 001-37852 241179557 34 8528874 1 1
2024-08-06 8-K FORM 8-K 2.02,9.01 0001104659-24-086088 001-37852 241177061 34 312132 1 1
2024-07-26 4 OWNERSHIP DOCUMENT 0001104659-24-083039 8796
2024-07-24 144 xsl144X01/primary_doc.xml 0001950047-24-005589 001-37852 241138481 33 5721
2024-06-26 8-K FORM 8-K 5.03,5.07,9.01 0001104659-24-075162 001-37852 241073564 34 225919 1 1
2024-06-17 4 OWNERSHIP DOCUMENT 0001104659-24-072307 5109
2024-06-11 4 OWNERSHIP DOCUMENT 0001104659-24-070420 8800
2024-06-11 4 OWNERSHIP DOCUMENT 0001104659-24-070419 5817
2024-06-07 144 xsl144X01/primary_doc.xml 0001950047-24-004533 001-37852 241030314 33 5009
2024-06-07 144 xsl144X01/primary_doc.xml 0001968582-24-000473 001-37852 241029860 33 6316
2024-05-07 10-Q 10-Q 0001558370-24-007081 001-37852 24922881 34 6848509 1 1
2024-05-07 8-K FORM 8-K 2.02,9.01 0001104659-24-058036 001-37852 24922435 34 301118 1 1
2024-04-26 ARS ARS 0001104659-24-053023 001-37852 24884611 34 2328488
2024-04-26 DEFA14A DEFA14A 0001104659-24-053013 001-37852 24884556 34 470766
2024-04-26 DEF 14A DEF 14A 0001104659-24-052999 001-37852 24884392 34 2945465 1 1
2024-04-19 4 OWNERSHIP DOCUMENT 0001104659-24-049567 5003
2024-04-12 PRE 14A FORM-PRE14A 0001104659-24-046797 001-37852 24841894 34 2960713 1 1
2024-04-02 4 OWNERSHIP DOCUMENT 0001104659-24-042744 5597
2024-04-01 144 xsl144X01/primary_doc.xml 0001968582-24-000271 001-37852 24809239 33 5759
2024-03-11 4 OWNERSHIP DOCUMENT 0001104659-24-033132 6950
2024-03-01 4 OWNERSHIP DOCUMENT 0001104659-24-030159 5596
2024-03-01 4 OWNERSHIP DOCUMENT 0001104659-24-030157 9268
2024-03-01 4 OWNERSHIP DOCUMENT 0001104659-24-030156 14510
2024-03-01 144 xsl144X01/primary_doc.xml 0001972362-24-000296 001-37852 24712527 33 6091
2024-03-01 144 xsl144X01/primary_doc.xml 0001950047-24-001667 001-37852 24710484 33 5005
2024-03-01 144 xsl144X01/primary_doc.xml 0001968582-24-000154 001-37852 24710316 33 7870
2024-02-29 144 xsl144X01/primary_doc.xml 0001972362-24-000257 001-37852 24705538 33 4888
2024-02-28 4 OWNERSHIP DOCUMENT 0001104659-24-028888 5180
2024-02-28 4 OWNERSHIP DOCUMENT 0001104659-24-028886 5080
2024-02-27 S-8 FORM S-8 0001104659-24-028247 333-277409 24687832 33 79944
2024-02-27 10-K 10-K 0001558370-24-001850 001-37852 24687482 34 11791694 1 1
2024-02-27 8-K FORM 8-K 2.02,9.01 0001104659-24-028208 001-37852 24686851 34 303492 1 1
2024-02-20 4 OWNERSHIP DOCUMENT 0001104659-24-025685 5179
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023959 005-89601 24640015 34 138547
2024-02-14 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0000921895-24-000437 005-89601 24633127 34 280174
2024-02-14 SC 13G/A PROTAGONIST THERAPEUTICS, INC. 0000902664-24-001573 005-89601 24632374 34 62826
2024-02-14 SC 13G/A PROTAGONIST THERAPEUTICS, INC. 0000902664-24-001553 005-89601 24632250 34 65063
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021763 005-89601 24629309 34 13267
2024-02-07 SC 13G/A PROTAGONIST THERAPEUTICS, INC. 0000902664-24-001166 005-89601 24602186 34 103317
2024-02-02 SC 13G/A ptgx_13ga.htm 0000908834-24-000035 005-89601 24588979 34 507140
2024-01-31 8-K FORM 8-K 1.01 0001104659-24-008787 001-37852 24582888 34 214087 1 1
2024-01-24 SC 13G/A us74366e1029_012424.txt 0001086364-24-002344 005-89601 24555911 34 13854
2024-01-23 SC 13G/A Protagonist_Th_Inc.txt 0000093751-24-000104 005-89601 24550970 34 8713
2024-01-18 4 OWNERSHIP DOCUMENT 0001104659-24-004901 5092
2024-01-18 4 OWNERSHIP DOCUMENT 0001104659-24-004899 5063
2024-01-16 8-K FORM 8-K 8.01,9.01 0001104659-24-003903 001-37852 24533698 34 5580348 1 1
2024-01-11 4 OWNERSHIP DOCUMENT 0001104659-24-003435 8749
2024-01-09 144 xsl144X01/primary_doc.xml 0001950047-24-000244 001-37852 24524195 33 4931
2024-01-08 8-K FORM 8-K 7.01,9.01 0001104659-24-002073 001-37852 24518399 34 12795897 1 1
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001497 5747
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001496 5676
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001495 7576
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001494 5757
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001493 5580
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001492 7678
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001491 5683
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001490 9252
2024-01-04 4 OWNERSHIP DOCUMENT 0001104659-24-001489 7561
2023-12-18 SC 13G PROTAGONIST THERAPEUTICS, INC. 0000902664-23-005906 005-89601 231493920 34 70114
2023-12-15 4 OWNERSHIP DOCUMENT 0001104659-23-126419 5516
2023-12-13 144 xsl144X01/primary_doc.xml 0001968582-23-000772 001-37852 231484930 33 4718
2023-11-02 10-Q 10-Q 0001558370-23-017460 001-37852 231373482 34 6511532 1 1
2023-11-02 8-K FORM 8-K 2.02,9.01 0001104659-23-113828 001-37852 231373112 34 286460 1 1
2023-10-30 4 OWNERSHIP DOCUMENT 0001104659-23-112599 5671
2023-10-30 3 OWNERSHIP DOCUMENT 0001104659-23-112596 9412
2023-10-30 8-K FORM 8-K 5.02 0001104659-23-112592 001-37852 231360722 34 199922 1 1
2023-10-23 4 OWNERSHIP DOCUMENT 0001104659-23-110803 7187
2023-10-19 4 OWNERSHIP DOCUMENT 0001104659-23-110157 7322
2023-08-11 424B5 424B5 0001104659-23-090520 333-227216 231164631 33 18345
2023-08-03 10-Q 10-Q 0001558370-23-013245 001-37852 231140395 34 7253744 1 1
2023-08-03 8-K FORM 8-K 2.02,9.01 0001104659-23-087269 001-37852 231140142 34 278343 1 1
2023-07-05 8-K FORM 8-K 8.01,9.01 0001104659-23-077821 001-37852 231066693 34 27885879 1 1
2023-07-03 8-K FORM 8-K 3.01 0001104659-23-077599 001-37852 231065339 34 199036 1 1
2023-06-02 4 OWNERSHIP DOCUMENT 0001104659-23-067691 7434
2023-06-02 4 OWNERSHIP DOCUMENT 0001104659-23-067690 9141
2023-06-02 4 OWNERSHIP DOCUMENT 0001104659-23-067689 7197
2023-05-30 8-K FORM 8-K 5.07 0001104659-23-066057 001-37852 23976720 34 206477 1 1
2023-05-04 10-Q 10-Q 0001558370-23-008137 001-37852 23889389 34 6401181 1 1
2023-05-04 8-K FORM 8-K 2.02,9.01 0001104659-23-056018 001-37852 23889032 34 271306 1 1
2023-04-19 4 OWNERSHIP DOCUMENT 0001104659-23-047208 5384
2023-04-13 SC 13G PROTAGONIST THERAPEUTICS, INC. 0000902664-23-002591 005-89601 23818701 34 110254
2023-04-12 ARS ARS 0001104659-23-044685 001-37852 23816464 34 2974613
2023-04-12 DEFA14A DEFA14A 0001104659-23-044563 001-37852 23815685 34 446305
2023-04-12 DEF 14A DEF 14A 0001104659-23-044557 001-37852 23815661 34 2651803
2023-04-11 4 OWNERSHIP DOCUMENT 0001104659-23-044168 7299
2023-04-10 8-K FORM 8-K 8.01,9.01 0001104659-23-043353 001-37852 23809785 34 596432 1 1
2023-04-06 424B5 424B5 0001104659-23-042274 333-266595 23803795 33 995686
2023-04-04 424B5 424B5 0001104659-23-041529 333-266595 23798076 33 996068
2023-03-20 SC 13G SCHEDULE 13G 0000921895-23-000729 005-89601 23747053 34 291156
2023-03-15 S-8 FORM S-8 0001104659-23-032859 333-270573 23736015 33 74367
2023-03-15 10-K 10-K 0001558370-23-003906 001-37852 23735867 34 11919506 1 1
2023-03-15 8-K FORM 8-K 2.02,9.01 0001104659-23-032774 001-37852 23735274 34 287367 1 1
2023-03-10 8-K FORM 8-K 7.01 0001104659-23-031135 001-37852 23723394 34 199340 1 1
2023-02-14 SC 13G/A SCHEDULE 13G/A, AMENDMENT #2 0000899140-23-000381 005-89601 23629305 34 53303
2023-02-14 SC 13G/A PROTAGONIST THERAPEUTICS, INC. 0000902664-23-001711 005-89601 23623815 34 63324
2023-02-14 SC 13G/A AMENDMENT NO. 6 TO THE SCHEDULE 13G 0000921895-23-000478 005-89601 23620685 34 282455
2023-02-09 SC 13G/A 13ga5_protagonist.htm 0001175707-23-000047 005-89601 23607058 34 680821
2023-02-09 SC 13G SCHEDULE 13G 0001104659-23-016776 005-89601 23604058 34 13156
2023-01-31 SC 13G/A us74366e1029_013123.txt 0001306550-23-005158 005-89601 23571822 34 13544
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004739 11484
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004737 11203
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004735 5524
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004734 11366
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004732 11471
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004731 11405
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004730 7411
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004725 7158
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004722 7218
2023-01-18 4 OWNERSHIP DOCUMENT 0001104659-23-004721 8901
2023-01-11 SC 13G/A SCHEDULE 13G/A FOR PROTAGONIST THERAPEUTICS, INC. ON BEHALF OF JOHNSON & JOHNSON 0000904454-23-000019 005-89601 23523133 34 34492
2023-01-10 SC 13G/A Protagonist_Therapeutics_Inc.txt 0000093751-23-000007 005-89601 23519731 34 10791
2023-01-06 8-K FORM 8-K 5.02 0001104659-23-001872 001-37852 23515467 34 199461 1 1
2023-01-03 SC 13G SC 13G 0001104659-23-000357 005-89601 23502399 34 133618
2022-12-12 SC 13G/A filing.txt 0000315066-22-001871 005-89601 221456266 34 8230
2022-11-17 4 OWNERSHIP DOCUMENT 0001104659-22-119974 27488
2022-11-17 4 OWNERSHIP DOCUMENT 0001104659-22-119971 7594
2022-11-17 3 OWNERSHIP DOCUMENT 0001104659-22-119967 9231
2022-11-08 10-Q 10-Q 0001558370-22-016908 001-37852 221369717 34 7905438 1 1
2022-11-08 8-K FORM 8-K 2.02,9.01 0001104659-22-115933 001-37852 221369005 34 293938 1 1
2022-08-24 4 FORM 4 SUBMISSION 0000899243-22-029621 7126
2022-08-16 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-08-16 16:00:00 9999999995-22-002399 333-266595 221172020 33 1903
2022-08-12 CORRESP filename1.htm 0001104659-22-090043 7703
2022-08-09 UPLOAD filename1.pdf 0000000000-22-008438 40376
2022-08-05 S-3 S-3 0001104659-22-086733 333-266595 221141360 33 1435864
2022-08-04 10-Q 10-Q 0001558370-22-012277 001-37852 221137537 34 7844843 1 1
2022-08-04 8-K FORM 8-K 2.02,9.01 0001104659-22-086131 001-37852 221136645 34 296090 1 1
2022-07-11 SC 13G/A PROTAGONIST_THERAPEUTICS_INC.txt 0000093751-22-000567 005-89601 221076313 34 10523
2022-06-10 SC 13G/A filing.txt 0000315066-22-001626 005-89601 221008012 34 8158
2022-06-02 8-K FORM 8-K 5.07 0001104659-22-067589 001-37852 22990686 34 215543 1 1
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065869 5662
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065866 5591
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065863 5616
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065862 5672
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065860 5495
2022-05-27 4 OWNERSHIP DOCUMENT 0001104659-22-065859 5598
2022-05-05 10-Q 10-Q 0001558370-22-007438 001-37852 22897288 34 7286822 1 1
2022-05-04 4 OWNERSHIP DOCUMENT 0001104659-22-056000 13012
2022-05-04 4 OWNERSHIP DOCUMENT 0001104659-22-055995 7029
2022-05-04 8-K FORM 8-K 2.02,9.01 0001104659-22-055918 001-37852 22892662 34 294978 1 1
2022-04-26 4 OWNERSHIP DOCUMENT 0001104659-22-050560 13527
2022-04-26 4 OWNERSHIP DOCUMENT 0001104659-22-050551 13233
2022-04-26 8-K FORM 8-K 7.01,9.01 0001104659-22-049856 001-37852 22851626 34 5004741 1 1
2022-04-19 4 OWNERSHIP DOCUMENT 0001104659-22-047468 7522
2022-04-19 3 OWNERSHIP DOCUMENT 0001104659-22-047462 9216
2022-04-14 4 OWNERSHIP DOCUMENT 0001104659-22-046158 7025
2022-04-13 DEFA14A DEFA14A 0001104659-22-045551 001-37852 22825324 34 5345196
2022-04-13 DEF 14A DEF 14A 0001104659-22-045545 001-37852 22825301 34 2090880
2022-04-13 8-K FORM 8-K 8.01,9.01 0001104659-22-045517 001-37852 22825004 34 10653350 1 1
2022-03-31 8-K FORM 8-K 5.02 0001104659-22-041035 001-37852 22792642 34 205648 1 1
2022-03-23 8-K FORM 8-K 5.02 0001104659-22-037018 001-37852 22763211 34 200365 1 1
2022-03-02 4 OWNERSHIP DOCUMENT 0001104659-22-029522 4934
2022-03-02 4 OWNERSHIP DOCUMENT 0001104659-22-029520 5075
2022-03-02 4 OWNERSHIP DOCUMENT 0001104659-22-029519 5023
2022-02-28 S-8 FORM S-8 0001104659-22-028156 333-263097 22690984 33 365319
2022-02-28 10-K 10-K 0001558370-22-002385 001-37852 22690740 34 11584071 1 1
2022-02-28 8-K FORM 8-K 2.02,9.01 0001104659-22-028113 001-37852 22690083 34 343599 1 1
2022-02-22 8-K FORM 8-K 5.02 0001104659-22-025661 001-37852 22658547 34 201966 1 1
2022-02-17 4 OWNERSHIP DOCUMENT 0001104659-22-024841 7415
2022-02-17 4 OWNERSHIP DOCUMENT 0001104659-22-024840 7525
2022-02-17 4 OWNERSHIP DOCUMENT 0001104659-22-024838 7435
2022-02-17 4 OWNERSHIP DOCUMENT 0001104659-22-024835 7356
2022-02-14 SC 13G/A SCHEDULE 13G/A, AMENDMENT #1 0000899140-22-000317 005-89601 22633153 34 66757
2022-02-14 SC 13G/A CONSONANCE CAPITAL MANAGEMENT LP 0001085146-22-001037 005-89601 22629186 34 46736
2022-02-14 SC 13G/A PROTAGONIST THERAPEUTICS, INC 0000902664-22-001579 005-89601 22625414 34 62124
2022-02-14 SC 13G/A AMENDMENT NO. 5 TO THE SCHEDULE 13G 0000921895-22-000451 005-89601 22624172 34 289368
2022-02-11 SC 13G/A AMENDMENT #4 0000908834-22-000091 005-89601 22621257 34 458632
2022-02-10 SC 13G PROTAGONIST_THERAPEUTICS_INC.txt 0000093751-22-000155 005-89601 22613668 34 8648
2022-02-09 SC 13G/A filing.txt 0000315066-22-001301 005-89601 22604784 34 8627
2022-02-03 SC 13G/A us74366e1029_020222.txt 0000834237-22-005353 005-89601 22585615 34 13570
2021-12-23 4 OWNERSHIP DOCUMENT 0001104659-21-153135 5283
2021-11-03 10-Q 10-Q 0001558370-21-014338 001-37852 211376488 34 10317616 1 1
2021-11-03 8-K FORM 8-K 2.02,9.01 0001104659-21-133637 001-37852 211375386 34 309420 1 1
2021-09-21 4 OWNERSHIP DOCUMENT 0001104659-21-118054 7315
2021-09-21 SC 13G SCHEDULE 13G 0000899140-21-000651 005-89601 211266904 34 67637
2021-09-17 8-K FORM 8-K 8.01,9.01 0001104659-21-117017 001-37852 211261437 34 229269 1 1
2021-08-19 4 OWNERSHIP DOCUMENT 0001104659-21-107818 9420
2021-08-10 8-K FORM 8-K 1.01 0001104659-21-102543 001-37852 211158463 34 213240 1 1
2021-08-04 10-Q 10-Q 0001558370-21-010244 001-37852 211144622 34 8442629 1 1
2021-08-04 8-K FORM 8-K 2.02,9.01 0001104659-21-100078 001-37852 211144165 34 303478 1 1
2021-07-28 8-K FORM 8-K 1.01 0001104659-21-096941 001-37852 211122642 34 226071 1 1
2021-06-17 8-K FORM 8-K 8.01,9.01 0001104659-21-082678 001-37852 211025488 34 626032 1 1
2021-06-17 424B5 424B5 0001104659-21-082601 333-251254 211024789 33 1150252
2021-06-14 424B5 424B5 0001104659-21-080855 333-251254 211015503 33 1200622
2021-06-14 8-K FORM 8-K 8.01,9.01 0001104659-21-080820 001-37852 211015187 34 3576811 1 1
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036680 5833
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036670 5818
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036667 5651
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036664 5751
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036663 5781
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036662 5759
2021-05-28 8-K FORM 8-K 5.07 0001104659-21-074317 001-37852 21981636 34 210419 1 1
2021-05-04 10-Q 10-Q 0001558370-21-005733 001-37852 21889480 34 7164182 1 1
2021-05-04 8-K FORM 8-K 2.02,9.01 0001104659-21-060967 001-37852 21888442 34 289766 1 1
2021-04-14 DEFA14A DEFA14A 0001104659-21-050207 001-37852 21825839 34 1302171
2021-04-14 DEF 14A DEF 14A 0001104659-21-050202 001-37852 21825804 34 1856038
2021-03-10 S-8 FORM S-8 0001104659-21-034494 333-254090 21730304 33 85951
2021-03-10 10-K 10-K 0001558370-21-002715 001-37852 21730186 34 11515298 1 1
2021-03-10 8-K FORM 8-K 2.02,9.01 0001104659-21-034431 001-37852 21729684 34 304139 1 1
2021-02-26 4 FORM 4 SUBMISSION 0001209191-21-014984 7485
2021-02-26 4 FORM 4 SUBMISSION 0001209191-21-014981 7388
2021-02-26 4 FORM 4 SUBMISSION 0001209191-21-014976 7582
2021-02-26 4 FORM 4 SUBMISSION 0001209191-21-014973 7476
2021-02-26 4 FORM 4 SUBMISSION 0001209191-21-014967 7488
2021-02-17 SC 13G CONSONANCE CAPITAL MANAGEMENT LP 0001085146-21-001026 005-89601 21643996 34 58445
2021-02-16 SC 13G CONSONANCE CAPITAL MANAGEMENT LP 0001085146-21-000931 005-89601 21636238 34 57982
2021-02-16 SC 13G/A AMENDMENT NO. 4 TO THE SCHEDULE 13G 0000921895-21-000409 005-89601 21631532 34 294939
2021-02-16 SC 13G/A AMENDMENT NO. 3 0001214659-21-001721 005-89601 21630859 34 312621
2021-02-12 4 FORM 4 SUBMISSION 0001209191-21-010401 17465
2021-02-12 SC 13G/A form-sc13ga.htm 0001493152-21-003507 005-89601 21623422 34 192642
2021-02-11 SC 13G/A PROTAGONIST THERAPEUTICS, INC. 0000902664-21-001142 005-89601 21616811 34 108277
2021-02-08 SC 13G/A filing.txt 0000315066-21-001243 005-89601 21599805 34 8646
2021-02-02 SC 13G us74366e1029_020221.txt 0000834237-21-006869 005-89601 21580630 34 13392
2021-02-02 SC 13G/A SCHEDULE 13G/A 0000904454-21-000100 005-89601 21578024 34 38451

Latest XBRL company facts

One latest value per concept from companyfacts (356 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 65.27M 2026-10-31 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
dei EntityPublicFloat Entity Public Float USD 2.90B 2025-06-30 2025 FY 10-K 2026-02-25 0001104659-26-019696
ecd AwardExrcPrice AwardExrcPrice USD/shares 38.09 2025-01-06 DEF 14A 2026-04-28 0001104659-26-050429
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 11.66M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 3.68M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 124.75 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 46.07M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd PeoTotalCompAmt PeoTotalCompAmt USD 12.87M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 433.23 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001104659-26-050429
ecd UndrlygSecurityMktPriceChngPct UndrlygSecurityMktPriceChngPct pure 0.5 2025-01-02 DEF 14A 2026-04-28 0001104659-26-050429
ffd NetFeeAmt NetFeeAmt USD 12,126.35 2026-08-03 S-8 2026-08-05 0001104659-26-091226
ffd TtlFeeAmt TtlFeeAmt USD 12,126.35 2026-08-03 S-8 2026-08-05 0001104659-26-091226
ffd TtlOfferingAmt TtlOfferingAmt USD 87.81M 2026-08-03 S-8 2026-08-05 0001104659-26-091226
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-03 S-8 2026-08-05 0001104659-26-091226
srt StockRepurchaseProgramAuthorizedAmount1 StockRepurchaseProgramAuthorizedAmount1 USD 300.00M 2026-09-08 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 5.92M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 3.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 11.26M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 4.22M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 26.56M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 642,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 9.53M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.29M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.18B 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 42.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 25,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 33.81M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 42.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 21,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001558370-20-005785
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 900,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap Assets Assets USD 1.15B 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AssetsCurrent Assets, Current USD 1.10B 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 135.18M 2018-09-30 2018 Q3 10-Q 2018-11-06 0001558370-18-008657
us-gaap AvailableForSaleSecuritiesCurrent Available-for-sale Securities, Current USD 42.47M 2019-03-31 2019 Q1 10-Q 2019-05-08 0001558370-19-004481
us-gaap AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value USD 100.01M 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 0 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap AvailableForSaleSecuritiesNoncurrent Available-for-sale Securities, Noncurrent USD 11.46M 2017-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 54,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CapitalizedContractCostNet Capitalized Contract Cost, Net USD 0 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 498.30M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 17.03M 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 498.58M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 369.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 457.78M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0.001 2023-08-31 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 1.50M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 0 2024-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 2.56M 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 180.00M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 65.26M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 65.22M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD 384.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract USD -8.19M 2019-04-01 2019-06-30 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap ContractWithCustomerAssetGrossCurrent Contract with Customer, Asset, before Allowance for Credit Loss, Current USD 165.00M 2024-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap ContractWithCustomerAssetNet Contract with Customer, Asset, after Allowance for Credit Loss USD 25.15M 2022-03-31 2023 Q1 10-Q 2023-05-04 0001558370-23-008137
us-gaap ContractWithCustomerAssetNetCurrent Contract with Customer, Asset, after Allowance for Credit Loss, Current USD 4.01M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 6.30M 2026-03-31 2026 Q1 10-Q 2026-05-05 0001104659-26-055661
us-gaap ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized USD 8.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 3,000 2023-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 23.79M 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 22.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Contract with Customer, Performance Obligation Satisfied in Previous Period USD 0 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-06 0001558370-18-008657
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 66.90M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 8.58M 2016-08-16 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap CostOfRevenue Cost of Revenue USD 1.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CostsAndExpenses Costs and Expenses USD 170.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 4.08M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD -88,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 838,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 838,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 1.02M 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-14 0001193125-16-767928
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 10.00M 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage pure 0.099 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.079 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 78,000 2023-01-01 2023-06-30 2024 Q2 10-Q 2024-08-06 0001558370-24-011095
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 222,000 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DeferredFinanceCostsNoncurrentGross Debt Issuance Cost, Gross, Noncurrent USD 235,000 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 1.39M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap DeferredIncomeCurrent Deferred Income, Current USD 16.31M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap DeferredIncomeTaxAssetsNet Deferred Income Tax Assets, Net USD 1.43M 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 1.39M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 1.71M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 1.47M 2016-06-30 2016 Q2 10-Q 2016-09-15 0001193125-16-710986
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 799,000 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap DeferredRevenue Deferred Revenue USD 31.75M 2017-12-31 2017 FY 10-K 2018-03-07 0001558370-18-001637
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 11.68M 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 1.30M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 168.85M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap DeferredTaxAssetsLiabilitiesNetNoncurrent Deferred Tax Assets, Net, Noncurrent USD 478,000 2019-03-31 2019 Q1 10-Q 2019-05-08 0001558370-19-004481
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 1.43M 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 54.05M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 1.10M 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 600,000 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 529,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 51.96M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 14.27M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 908,000 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 167.14M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 1.71M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DefinedContributionPlanAdministrativeExpenses Defined Contribution Plan, Administrative Expense USD 200,000 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-04 0001558370-21-005733
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 0 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap Depreciation Depreciation USD 1.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap DueFromAffiliateCurrent Due from Affiliate, Current USD 5.79M 2018-06-30 2018 Q2 10-Q 2018-08-07 0001558370-18-006639
us-gaap DueFromRelatedPartiesCurrent Due from Related Parties, Current USD 39,000 2023-06-30 2023 Q2 10-Q 2023-08-03 0001558370-23-013245
us-gaap DueToAffiliateCurrent Due to Affiliate, Current USD 276,000 2018-06-30 2018 Q2 10-Q 2018-08-07 0001558370-18-006639
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 10,000 2023-06-30 2023 Q2 10-Q 2023-08-03 0001558370-23-013245
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares 5.88 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.27 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001558370-22-012277
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares 5.43 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.006 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.342 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.312 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0.002 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure 0.049 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.017 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.006 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.037 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0.029 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD 22,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD -90,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 78.00M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap ForeignCurrencyTransactionLossBeforeTax Foreign Currency Transaction Loss, before Tax USD 549,000 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-04 0001558370-21-005733
us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations Foreign Income Tax Expense (Benefit), Continuing Operations USD -1.10M 2019-01-01 2019-09-30 2020 Q3 10-Q 2020-11-04 0001558370-20-012597
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -8,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0001558370-22-002385
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -585,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 39.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -129.79M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD 393.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 476,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxCreditsAndAdjustments Income Tax Credits and Adjustments USD 1.44M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 3.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current AUD 3.80M 2022-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap IncomeTaxExaminationPenaltiesAndInterestExpense Income Tax Examination, Penalties and Interest Expense USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 7.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 2.67M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 1.02M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 44.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -27.16M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 112,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD -6.35M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -2.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 838,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 4.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 696,000 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-08 0001558370-19-004481
us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Increase (Decrease) in Accounts Payable, Related Parties USD -3,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap IncreaseDecreaseInAccountsPayableTrade Increase (Decrease) in Accounts Payable, Trade USD 563,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInAccountsReceivableRelatedParties Increase (Decrease) in Accounts Receivable, Related Parties USD 155.00M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap IncreaseDecreaseInAccruedIncomeTaxesPayable Increase (Decrease) in Income Taxes Payable USD 4.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInContractWithCustomerAsset Increase (Decrease) in Contract with Customer, Asset USD 4.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 6.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 31.75M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001558370-18-001637
us-gaap IncreaseDecreaseInIncomeTaxesReceivable Increase (Decrease) in Income Taxes Receivable USD -2.69M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -1.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities USD -5.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 832,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD -121,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-27 0001558370-24-001850
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap IncreaseInCarryingAmountOfRedeemablePreferredStock Increase in Carrying Amount of Redeemable Preferred Stock USD 558,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap InterestExpense Interest Expense USD 598,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 438,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap InterestPayableCurrent Interest Payable, Current USD 68,000 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 3.12M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 20.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap LeaseCost Lease, Cost USD 2.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 11.48M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 895,000 2019-09-30 2019 Q3 10-Q 2019-11-06 0001558370-19-010201
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 2.79M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 895,000 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 2.83M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 2.98M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 2.88M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 223,000 2024-09-30 2024 Q3 10-Q 2024-11-07 0001558370-24-014888
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 1.16M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap Liabilities Liabilities USD 61.64M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.15B 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap LiabilitiesCurrent Liabilities, Current USD 55.46M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 2.12M 2015-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap LongTermDebt Long-term Debt USD 9.79M 2019-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap LongTermDebtFairValue Long-term Debt, Fair Value USD 0 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 301.77M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 34.56M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 5,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 41.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 492,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 181.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 11.07M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD 146.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD 18.02M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD 386.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -38.92M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Noncash or Part Noncash Acquisition, Fixed Assets Acquired USD 185,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OperatingExpenses Operating Expenses USD 114.72M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-05 0001104659-26-091123
us-gaap OperatingIncomeLoss Operating Income (Loss) USD 373.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 1.50M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0001558370-24-001850
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 10.32M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 2.45M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 6.18M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OperatingLeasePayments Operating Lease, Payments USD 903,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 6.50M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 2.07M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-21 0001558370-25-001317
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 11.23M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 1.94M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 2.19M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.12M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 2.06M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 2.00M 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 922,000 2018-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 477,000 2018-09-30 2018 Q3 10-Q 2018-11-06 0001558370-18-008657
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 1.90M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.057 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OtherAccountsPayableAndAccruedLiabilities Other Accounts Payable and Accrued Liabilities USD 26.56M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 577,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherAssetsCurrent Other Assets, Current USD 10,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 832,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD 73,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-06 0001558370-19-010201
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent USD 194,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD 21,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD 324,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -143,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -1.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -1.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 121,000 2020-12-31 2021 FY 10-K 2022-02-28 0001558370-22-002385
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -42,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherOperatingActivitiesCashFlowStatement Other Operating Activities, Cash Flow Statement USD -5,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 6.12M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 11,000 2023-06-30 2023 Q2 10-Q 2023-08-03 0001558370-23-013245
us-gaap PaymentsForProceedsFromTenantAllowance Payments for (Proceeds from) Tenant Allowance USD 469,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 5.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 14,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 25,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001558370-22-012277
us-gaap PaymentsToAcquireAvailableForSaleSecurities Payments to Acquire Available-for-sale Securities USD 21.73M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-08 0001558370-19-004481
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 212.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 620,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 13.20M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PrepaidInsurance Prepaid Insurance USD 190,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 24.30M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 107.80M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 991,000 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 9.77M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0001558370-22-002385
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 22.51M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 46.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ProceedsFromLeasePayments Proceeds from Lease Payment, Operating Activity USD 341,000 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-06 0001558370-25-006530
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 391.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 3.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 32,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 151,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 789,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 559,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD 386.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 12.85M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 3.32M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ReceivablesLongTermContractsOrPrograms Receivables, Long-term Contracts or Programs USD 283.79M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 10.52M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 130.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 10,000 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 10,000 2020-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 287,000 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap RestructuringCharges Restructuring Charges USD 300,000 2020-03-07 2021 FY 10-K 2022-02-28 0001558370-22-002385
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -84.02M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 544.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 56.37M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-05 0001104659-26-055661
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 20.06M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001558370-18-001637
us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount USD 96.30M 2021-03-31 2021 Q2 10-Q 2021-08-04 0001558370-21-010244
us-gaap Revenues Revenues USD 8.78M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 10.51M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 20 2023-04-30 2023 FY 10-K 2024-02-27 0001558370-24-001850
us-gaap SecurityDeposit Security Deposit USD 225,000 2026-03-31 2026 Q1 10-Q 2026-05-05 0001104659-26-055661
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 42.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period shares 26,727 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value USD/shares 8.97 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 142,000 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 7.8 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 262,608 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 9.24 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 131,147 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value USD/shares 9.52 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-06 0001558370-20-009681
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-03 0001558370-23-013245
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.525 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-07 0001558370-18-001637
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.902 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-04 0001558370-21-010244
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.88 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-04 0001558370-21-010244
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.02 2017-07-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001377121-17-000007
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.011 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-04 0001558370-21-010244
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.001 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-04 0001558370-21-010244
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 362.50M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 5.35M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 19.58 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 39.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 32.48 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 501.30M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 7.67M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 21.99 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 29.80M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 501.30M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 7.67M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 21.99 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 20.64 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 26.28 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 40.93 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 51,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 1.08B 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.069 2016-07-01 2016-07-31 2017 FY 10-K 2018-03-07 0001558370-18-001637
us-gaap StockIssued1 Stock Issued USD 1.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 5.00M 2023-04-01 2023-04-30 2023 FY 10-K 2024-02-27 0001558370-24-001850
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Stock Issued During Period, Shares, Restricted Stock Award, Forfeited shares 200,110 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 1.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 66.90M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 24.30M 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-04 0001558370-23-008137
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD 48.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 151,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD 6.67M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 40,560 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 5.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount USD 294.20M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap SubleaseIncome Sublease Income USD 34,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap TangibleAssetImpairmentCharges Tangible Asset Impairment Charges USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-10 0001558370-21-002715
us-gaap TemporaryEquityAccretionToRedemptionValue Temporary Equity, Accretion to Redemption Value USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 558,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 37.00M 2015-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 41.54M 2015-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 126.37M 2015-12-31 2018 FY 10-K 2019-03-12 0001558370-19-001853
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2016-12-31 2016 FY 10-K 2017-03-07 0001193125-17-073383
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2022-12-31 2022 FY 10-K 2023-03-15 0001558370-23-003906
us-gaap TreasuryStockCommonValue Treasury Stock, Common, Value USD 5.79M 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 36.97M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 902,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 5.33M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 1.07M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 4.10M 2019-12-31 2019 FY 10-K 2020-03-10 0001558370-20-002334
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 51.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019696
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 5.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 71.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 48.90M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001558370-22-012277
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 65.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-06 0001104659-26-123620

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →